These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

814 related items for PubMed ID: 16267020

  • 1. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 2. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX, Yang X, Sreejayan N, Ren J.
    Exp Neurol; 2007 Jan 01; 203(1):196-204. PubMed ID: 16962100
    [Abstract] [Full Text] [Related]

  • 3. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM.
    Cancer Res; 2007 May 01; 67(9):4287-94. PubMed ID: 17483341
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ, Rudin CM.
    Mol Cancer Res; 2005 Nov 01; 3(11):635-44. PubMed ID: 16317089
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J, Sassano A, Hay N, Platanias LC.
    Clin Cancer Res; 2008 Jul 15; 14(14):4640-9. PubMed ID: 18628479
    [Abstract] [Full Text] [Related]

  • 7. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M, Rowinsky EK.
    Oncogene; 2000 Dec 27; 19(56):6680-6. PubMed ID: 11426655
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.
    Clin Cancer Res; 2004 Sep 01; 10(17):5820-7. PubMed ID: 15355912
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smelley CL, Caldito GC, Abreo FW, Nathan CO.
    Cancer Prev Res (Phila); 2010 Dec 01; 3(12):1586-95. PubMed ID: 20851953
    [Abstract] [Full Text] [Related]

  • 13. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A.
    Cancer; 2009 Jan 01; 115(1):107-18. PubMed ID: 19090006
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
    Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Riefkohl W, Law A, Wood GC, Kennedy TL.
    Ann Clin Lab Sci; 2006 Jan 01; 36(3):273-82. PubMed ID: 16951268
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB.
    Clin Cancer Res; 2008 Oct 01; 14(19):6228-36. PubMed ID: 18829502
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, Dugu L, Tu Y, Moroi Y, Furue M.
    Br J Dermatol; 2009 Aug 01; 161(2):357-63. PubMed ID: 19438435
    [Abstract] [Full Text] [Related]

  • 19. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S.
    Oncogene; 2006 Nov 09; 25(53):7029-40. PubMed ID: 16715128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.